Our study shows that XPF is highly variable among head and neck cancers with a wide dynamic range: Low levels of expression of XPF correlate with better response to induction chemoradiotherapy, while high levels of XPF expression are associated with a worse response. Here, ERCC4 is linked to head and neck cancer.